Table 3.

Comparison of clinical outcomes in propensity-matched groups.

Clinical outcomes	CBP group (n = 213)	non-CBP group (n = 213)	aOR (95% CI); p‡
VPA serum concentration (mg/L), median (IQR)	15.8 (7.5-24.9); (n = 192)	60.8 (48.3-79.0); (n = 191)	p < 0.0001*
Epileptic seizures during concomitant administration, n (%)	109 (51.2)	69 (32.4)	2.19 (1.48–3.24); p < 0.0001
Status epilepticus during concomitant administration, n (%)	29 (13.6)	10 (4.7)	3.20 (1.51–6.74); p = 0.0014
In-hospital mortality rate, n (%)	72 (33.8)	53 (24.9)	1.57 (1.03–2.20); p = 0.036
Length of hospital stay after concomitant administration (days), median (IQR)	41 (23–66)	30 (26–48)	p < 0.001*
Expenditure of healthcare, U.S. dollars, median (IQR)	20,970 (13,321.4-34,549.1)	12,848 (7,314.4-22,831.6)	p < 0.0001*

aOR, adjusted odds ratio; CBP, carbapenem antibiotics; CI, confidence interval; IQR, interquartile range; n, number;

^‡P-value is reported for Chi-square test unless otherwise stated;

^*P-value is reported for Wilcoxon test; VPA, valproic acid.